(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia...
Stats | |
---|---|
Šios dienos apimtis | 25.13M |
Vidutinė apimtis | 9.60M |
Rinkos kapitalizacija | 10.23B |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0.0600 ( 2020-06-29 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 18.13 |
ATR14 | HKD0.00900 (0.33%) |
Tūris Koreliacija
Luye Pharma Group Ltd Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Luye Pharma Group Ltd Koreliacija - Valiuta/Žaliavos
Luye Pharma Group Ltd Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD6.14B |
Bruto pelnas: | HKD4.20B (68.44 %) |
EPS: | HKD0.140 |
FY | 2023 |
Pajamos: | HKD6.14B |
Bruto pelnas: | HKD4.20B (68.44 %) |
EPS: | HKD0.140 |
FY | 2022 |
Pajamos: | HKD5.98B |
Bruto pelnas: | HKD4.14B (69.22 %) |
EPS: | HKD0.170 |
FY | 2021 |
Pajamos: | HKD5.20B |
Bruto pelnas: | HKD3.40B (65.32 %) |
EPS: | HKD-0.0422 |
Financial Reports:
No articles found.
Luye Pharma Group Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0370 | 2016-10-04 |
Last Dividend | HKD0.0600 | 2020-06-29 |
Next Dividend | HKD0 | N/A |
Payout Date | 2020-07-24 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.406 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.99 | -- |
Div. Sustainability Score | 8.62 | |
Div.Growth Potential Score | 4.10 | |
Div. Directional Score | 6.36 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2633.HK | Ex Dividend Knight | 2023-08-15 | Semi-Annually | 0 | 0.00% | |
1412.HK | Ex Dividend Knight | 2023-06-12 | Semi-Annually | 0 | 0.00% | |
0497.HK | Ex Dividend Junior | 2023-08-25 | Annually | 0 | 0.00% | |
6837.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
1962.HK | Ex Dividend Junior | 2023-09-11 | Annually | 0 | 0.00% | |
0992.HK | Ex Dividend Knight | 2023-07-26 | Semi-Annually | 0 | 0.00% | |
0104.HK | Ex Dividend Knight | 2023-08-16 | Sporadic | 0 | 0.00% | |
3328.HK | Ex Dividend Junior | 2023-07-04 | Annually | 0 | 0.00% | |
1569.HK | Ex Dividend Junior | 2023-07-20 | Annually | 0 | 0.00% | |
0598.HK | Ex Dividend Knight | 2023-09-08 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0867 | 1.500 | 8.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0209 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0446 | 1.500 | -0.615 | -0.923 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.315 | 0.800 | 8.42 | 6.74 | [1 - 3] |
quickRatioTTM | 0.844 | 0.800 | 9.74 | 7.79 | [0.8 - 2.5] |
cashRatioTTM | 0.398 | 1.500 | 8.90 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.330 | -1.500 | 4.50 | -6.76 | [0 - 0.6] |
interestCoverageTTM | 2.56 | 1.000 | -0.164 | -0.164 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.183 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0387 | 2.00 | 9.98 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.671 | -1.500 | 7.32 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.684 | 1.000 | 1.927 | 1.927 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.144 | 1.000 | 9.11 | 9.11 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0821 | 1.000 | -0.655 | -0.655 | [0.2 - 2] |
assetTurnoverTTM | 0.241 | 0.800 | -1.727 | -1.381 | [0.5 - 2] |
Total Score | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.77 | 1.000 | 8.31 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0446 | 2.50 | -0.395 | -0.923 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0387 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.183 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.601 | 1.500 | 2.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.112 | 1.000 | 9.69 | 0 | [0.1 - 0.5] |
Total Score | 4.10 |
Luye Pharma Group Ltd
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.